A role of MAGI2 in prostate tumorigenesis has been also evaluated; mutations in MAGI2 contribute to prostate carcinogenesis by driving AKT phosphorylation and altering PI3K signaling, thus disrupting PTEN signaling [56]. Here, MAGI2 is linked to medical procedure.